Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Immunogenicity and Safety Study of a Three-Dose BioThrax Regimen for Post-Exposure Prophylaxis in Healthy Adults.

Next Previous
Trial Profile

Immunogenicity and Safety Study of a Three-Dose BioThrax Regimen for Post-Exposure Prophylaxis in Healthy Adults.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 11 Apr 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anthrax vaccine (Primary)
  • Indications Anthrax
  • Focus Pharmacodynamics; Registrational
  • Sponsors Emergent BioSolutions

    • Most Recent Events

    • 24 Nov 2015 According to Emergent BioSolutions media release, BioThrax (Anthrax Vaccine Adsorbed) received supplemental Biologics License from U.S FDA
    • 23 Nov 2015 According to the FDA media release, BioThrax is the first vaccine approved on the basis of Animal Rule.
    • 23 Nov 2015 According to the FDA media release, BioThrax (Anthrax Vaccine Adsorbed) received approval from U.S. FDA for a new indication, to prevent disease following suspected or confirmed exposure to Bacillus anthracis.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top